3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
41
Stomach Neoplasms
3
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Sarcoma, Synovial
1
Rhabdomyosarcoma
1
Pleuropulmonary blastoma
1
Patient Preference
1
Pancreatic Neoplasms
1
Neurofibrosarcoma
1
Neuroblastoma
1
Multiple Myeloma
1
Lymphoma
1
Inflammatory Breast Neoplasms
1
Hematologic Neoplasms
1
HER2-positive Breast Cancer
1
HER2 Positive Breast Cancer
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Advanced Unresectable or Metastatic Solid Malignancy
1
Interventions
Rituximab
4
blinatumomab
3
Whole-Body Irradiation
3
Cyclophosphamide
3
fludarabine phosphate
2
Mycophenolic Acid
2
Melphalan
2
Lenalidomide
2
Clofarabine
2
treosulfan
1
thymoglobulin
1
sabatolimab
1
pembrolizumab
1
peginterferon alfa-2a
1
obinutuzumab
1
midostaurin
1
ixazomib
1
fludarabine
1
eribulin
1
daratumumab
1
acalabrutinib
1
Trastuzumab
1
Tacrolimus
1
Sodium Chloride
1
Sirolimus
1
Peripheral Blood Stem Cell Transplantation
1
Pentostatin
1
N,N-dicyclohexyl-isoborneol-10-sulfonamide
1
Methotrexate
1
Magnetic Resonance Imaging
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Neoplasm, Residual
×
Ado-Trastuzumab Emtansine
×
Clear all
No trials found.